💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Methylprednisolone

CHEMBL650 Phase 4 Aprovado Small molecule
Half-Life
18-36 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
374.5 g/mol
LogP
1.9
Phase
4

An intermediate-acting synthetic glucocorticoid, methylprednisolone suppresses inflammation and immune activity across a wide range of conditions, including severe allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. Available in oral, injectable, and topical forms and marketed as Medrol and Depo-Medrol, it has the formula C22H30O5. Its potency relative to older steroids allows effective control of acute inflammatory episodes.

A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

Peso Molecular

374,4710 g/mol

LogP

1,90

TPSA

94,80 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Neurology Immunology Asthma Rheumatoid Arthritis Multiple Sclerosis Rheumatology

Classes de Medicamentos

H — H - Systemic Hormonal Preparations, Excluding Sex Hormones and Insulins

Mecanismo de Ação

Intermediate-acting synthetic glucocorticoid.

Pharmacokinetics (PK)

Half-Life 18-36 hours

Pharmacodynamics (PD)

Mecanismo

Intermediate-acting synthetic glucocorticoid.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H30O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
Ligações Rotacionáveis

                        
2

                    

                    
                    
                    

                        
Átomos Pesados

                        
27

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Diltiazem
                            
                        

                        
                        
Diltiazem inhibits CYP3A4-mediated methylprednisolone metabolism, increasing methylprednisolone exposure and the risk of steroid side effects including immunosuppression, hyperglycaemia, and hypertension.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4-mediated metabolism of methylprednisolone, increasing its plasma levels and prolonging corticosteroid effects, raising the risk of Cushingoid features.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Cyclosporine
                            
                        

                        
                        
Methylprednisolone inhibits CYP3A4-mediated cyclosporine metabolism, raising cyclosporine levels; conversely, cyclosporine may increase methylprednisolone exposure — a bidirectional pharmacokinetic interaction.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting synthetic glucocorticoid.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Methylprednisolone: Half-life: 18-36 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Methylprednisolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Levothyroxine
                            Small molecule
                        
                        
                        
                            Prednisone
                            Small molecule
                        
                        
                        
                            Dexamethasone
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL650.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6741.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.